1. Home
  2. HYFM vs MBAI Comparison

HYFM vs MBAI Comparison

Compare HYFM & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hydrofarm Holdings Group Inc.

HYFM

Hydrofarm Holdings Group Inc.

HOLD

Current Price

$1.37

Market Cap

11.2M

Sector

Industrials

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.75

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
HYFM
MBAI
Founded
1977
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
10.6M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
HYFM
MBAI
Price
$1.37
$1.75
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
25.0K
7.0M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$190,288,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$51.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$1.31
52 Week High
$5.80
$3.92

Technical Indicators

Market Signals
Indicator
HYFM
MBAI
Relative Strength Index (RSI) 35.54 49.76
Support Level $1.40 $1.71
Resistance Level $1.48 $1.88
Average True Range (ATR) 0.09 0.17
MACD -0.00 0.00
Stochastic Oscillator 0.00 66.64

Price Performance

Historical Comparison
HYFM
MBAI

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: